Bora Pharmaceuticals Co Ltd 6472
TWSE · Taiwan · Health Technology
TWD 429.50+5.50 (+1.30%)
Market closed· · TWD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · TWD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Upsher-Smith Laboratories, LLC (Upsher-Smith), a subsidiary of Bora Pharmaceuticals Co., Ltd. (6472.TW and BORAY.OTCQX), today announced the recent launch of Fluvoxamine Maleate Extended-Release Capsules in 100 mg and 150 mg strengths. According to IQVIA, the Fluvoxamine Maleate Extended-Release market had U.S. sales of approximately $44.6 million*.
Upsher-Smith Laboratories, LLC (Upsher-Smith), a subsidiary of Bora Pharmaceuticals Co., Ltd. (6472.TW and BORAY.OTCQX), today announced the recent launch of Glatiramer Acetate Injection in 20 mg/mL and 40 mg/mL strengths, adding to the Company's portfolio of complex generic medicines. According to IQVIA, the Glatiramer Acetate Injection market had U.S. sales of approximately $562 million*.
MAPLE GROVE, Minn., July 23, 2026--Bora Pharmaceuticals and Onconic Therapeutics Sign Manufacturing Agreement to Support U.S. Clinical Development of JAQBO Tablets
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.